{
    "root": "7abc1825-182d-40bc-9f7f-968e197b4246",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pravastatin Sodium",
    "value": "20250430",
    "ingredients": [
        {
            "name": "PRAVASTATIN SODIUM",
            "code": "3M8608UQ61",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "pravastatin sodium tablets indicated : \u2022to reduce risk myocardial infarction , myocardial revascularization procedures , cardiovascular mortality adults elevated low-density lipoprotein cholesterol ( ldl-c ) without clinically evident coronary heart disease ( chd ) . \u2022to reduce risk coronary death , myocardial infarction , myocardial revascularization procedures , stroke transient ischemic attack , slow progression coronary atherosclerosis adults clinically evident chd . \u2022as adjunct diet reduce ldl-c adults primary hyperlipidemia . \u2022as adjunct diet reduce ldl-c pediatric patients ages 8 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022as adjunct diet treatment adults : oprimary dysbetalipoproteinemia . ohypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "transient ischemic attack (DOID:224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_224"
            },
            {
                "text": "coronary atherosclerosis (DOID:0061139)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0061139"
            },
            {
                "text": "atherosclerosis (DOID:1936)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1936"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 take orally daily time day , without food ( 2.1 ) . \u2022 patients require high-intensity statin unable achieve ldl-c goal receiving pravastatin sodium tablets 80 mg daily , prescribe alternative ldl-c-lowering treatment ( 2.1 ) . \u2022 assess ldl-c clinically appropriate , early 4 weeks initiating pravastatin sodium tablets , adjust necessary ( 2.1 ) . \u2022 adults : recommended starting pravastatin sodium tablets 40 mg 80 mg daily . ( 2.2 ) \u2022 pediatric patients ( 2.3 ) : aged 8 13 years , recommended 20 mg daily . aged 14 18 years , recommended starting 40 mg daily . \u2022 severe renal impairment : recommended starting pravastatin sodium 10 mg daily . another pravastatin sodium product initiate dosing . recommended maximum pravastatin sodium tablets 40 mg daily . ( 2.4 ) \u2022 full prescribing information modifications due ( 2.5 , 7 ) .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u2022acute liver failure decompensated cirrhosis [ ] . \u2022hypersensitivity pravastatin excipients pravastatin sodium tablets .",
    "indications_original": "Pravastatin sodium tablets are indicated:\n                  \n                     \n                        \u2022To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).\n                     \n                        \u2022To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.\n                     \n                        \u2022As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.\n                     \n                        \u2022As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                     \n                        \u2022As an adjunct to diet for the treatment of adults with:\n                           \n                              oPrimary dysbetalipoproteinemia.\n                           \n                              oHypertriglyceridemia.",
    "contraindications_original": "\u2022 Take orally once daily at any time of the day, with or without food ( 2.1 ). \u2022 For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment ( 2.1 ). \u2022 Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium tablets, and adjust the dosage if necessary ( 2.1 ). \u2022 Adults: recommended starting dosage is pravastatin sodium tablets 40 mg to 80 mg once daily. ( 2.2 ) \u2022 Pediatric Patients ( 2.3 ): o aged 8 to 13 years, the recommended dosage is 20 mg once daily. o aged 14 to 18 years, the recommended starting dosage is 40 mg once daily. \u2022 Severe renal impairment: recommended starting dosage is pravastatin sodium 10 mg once daily. Use another pravastatin sodium product to initiate dosing. Recommended maximum pravastatin sodium tablets dosage is 40 mg once daily. ( 2.4 ) \u2022 See full prescribing information for dosage modifications due to drug interactions ( 2.5 , 7 ).",
    "adverseReactions_original": "\u2022Acute liver failure or decompensated cirrhosis [see \n                        ].\n                     \n                     \n                        \u2022Hypersensitivity to any pravastatin or any excipients in pravastatin sodium tablets.",
    "drug": [
        {
            "name": "Pravastatin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        }
    ]
}